13F Portfolios

Samsara BioCapital, LLC: NEUROGENE INC (NGNE): Quarterly 13F Position History

As of Q1 2026, Samsara BioCapital, LLC reported 1,717,127 shares of NEUROGENE INC (NGNE), worth $34.6M and representing 3.4% of its 13F equity book. The position first appeared in Q4 2023 and has been disclosed across 10 13F-HR filings in Pactolio's tracked window.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 10 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 1,717,127 0 $34.6M 3.4% $20.2
Q4 2025 1,717,127 0 $35.4M 3.6% $20.6
Q3 2025 1,717,127 0 $29.8M 3.9% $17.3
Q2 2025 1,717,127 0 $25.7M 5.3% $14.9
Q1 2025 1,717,127 0 $20.1M 3.6% $11.7
Q4 2024 1,717,127 +449,337 +35.4% $39.3M 5.4% $22.9
Q3 2024 1,267,790 0 $53.2M 10.2% $42.0
Q2 2024 1,267,790 0 $46.1M 9.7% $36.4
Q1 2024 1,267,790 0 $64.5M 10.0% $50.9
Q4 2023 1,267,790 $24.6M 3.8% $19.4

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Samsara BioCapital, LLC first disclose a NGNE position in 13F-HR filings?

Samsara BioCapital, LLC first reported NEUROGENE INC (NGNE) on its 13F-HR filing for the period ending 2023-12-31 (Q4 2023). The position has appeared on 10 reported quarters within Pactolio's tracked window.

What was Samsara BioCapital, LLC's most recent quarter-over-quarter share-count change in NGNE?

Samsara BioCapital, LLC held the same 1,717,127 shares of NGNE between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.

Does the implied price-per-share represent Samsara BioCapital, LLC's cost basis in NGNE?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.